LECANEMAB IN THE EARLY TREATMENT OF ALZHEIMER’S DISEASE: EVIDENCE AND PERSPECTIVES
DOI:
https://doi.org/10.63330/aurumpub.044-023Palabras clave:
Alzheimer, Beta-amyloid, Early therapy, Lecanemab, Monoclonal antibodiesResumen
This chapter aims to analyze recent scientific evidence regarding the use of lecanemab in the early treatment of Alzheimer’s disease, focusing on its efficacy, safety, and clinical implications. The methodology consisted of a narrative literature review based on randomized clinical trials, observational studies, and reports from regulatory agencies published between 2018 and 2025. The results indicate that lecanemab, a monoclonal antibody targeting beta-amyloid protein, has shown the ability to reduce amyloid plaque burden in the brain and slow cognitive decline in patients at early stages of the disease. Phase III studies demonstrated modest but statistically significant clinical benefits, particularly when administered early. However, adverse events such as amyloid-related imaging abnormalities were reported, requiring careful monitoring. It is concluded that lecanemab represents a significant advancement in disease-modifying therapy for Alzheimer’s disease, although challenges related to safety, cost, and accessibility still limit its widespread clinical use.
Descargas
Referencias
ALZHEIMER’S ASSOCIATION. 2023 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, v. 19, n. 4, p. 1598–1695, 2023.
CUMMINGS, Jeffrey; AISEN, Paul; LEMERE, Cynthia; AU, Rhoda; JACK JUNIOR, Clifford R. Aducanumab and lecanemab: anti-amyloid immunotherapy for Alzheimer’s disease. Nature Reviews Neurology, v. 19, p. 387–398, 2023.
FOOD AND DRUG ADMINISTRATION (FDA). FDA grants accelerated approval for Alzheimer’s disease treatment lecanemab. Silver Spring, 2023. Disponível em: https://www.fda.gov. Acesso em: 20 abr. 2026.
HARDY, John; SELKOE, Dennis J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, v. 297, n. 5580, p. 353–356, 2002.
JACK JUNIOR, Clifford R.; BENNETT, David A.; BLENNOW, Kaj; CARRILLO, Maria C.; DUNN, Brian; HAEGELE, Kevin et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, v. 14, n. 4, p. 535–562, 2018.
KNOPMAN, David S.; JONES, David T.; GREICIUS, Michael D. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials. Alzheimer’s & Dementia, v. 17, n. 4, p. 696–701, 2021.
SEVIGNY, Jeff; CHIAO, Ping; BOPAIAH, Sarita; WILLIAMS, Lisa; MAO, Cong; DANDY, Kathleen et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, v. 537, p. 50–56, 2016.
SELKOE, Dennis J.; HARDY, John. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, v. 8, n. 6, p. 595–608, 2016.
SWANSON, Christopher J.; ZHANG, Yiyi; DHADUK, Riddhi; KIM, Mina; LOPEZ, Jose; LEE, Sang et al. A randomized, double-blind, placebo-controlled phase 2b study of lecanemab in early Alzheimer’s disease. Alzheimer’s Research & Therapy, v. 13, n. 80, 2021.
VAN DYCK, Christopher H.; SWANSON, Christopher J.; AISEN, Paul; BATEMAN, Randall J.; CHEN, Cheng-Yi; HANSEN, Louise et al. Lecanemab in early Alzheimer’s disease. The New England Journal of Medicine, v. 388, p. 9–21, 2023.
WORLD HEALTH ORGANIZATION (WHO). Global status report on the public health response to dementia. Geneva: WHO, 2021.
Publicado
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
